€25.60
Your prediction
Agios Pharmaceuticals Inc. Stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 4.070% | 5.785% | 0.000% | -10.490% | 10.345% | 23.077% | -39.293% |
| United Therapeutics | -1.750% | 0.154% | 6.665% | 59.306% | 6.366% | 125.000% | 226.978% |
| Ligand Pharmaceuticals | -4.520% | -6.742% | 3.750% | 64.356% | 0.000% | 145.926% | 27.203% |
| Ionis Pharmaceuticals Inc. | 0.120% | 1.293% | -8.285% | 113.274% | -7.799% | 100.705% | 72.167% |
Comments
News
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME


